Analyst thinks RSV vaccine market could reach over USD 10bn

Glaxosmithkline, Johnson & Johnson and Pfizer are likely to win big on the sale of RSV vaccines, but Bavarian Nordic could also profit nicely off the billion-dollar market, analyst at investment bank Leerink assesses.

Even if Bavarian Nordic is a great deal behind others in the development of RSV vaccine, it could still profit off the billion-dollar market | Photo: Bavarian Nordic / PR

As companies move closer to completing a vaccine against the respiratory syncytial virus, a potentially very lucrative new market begins to emerge. It could even reach a size of USD 10.5bn in the next decade, estimates analyst at SVB Leerink Geoffrey Porges, according to Fiercepharma.

He thinks the well-established vaccine producers Glaxosmithkline, Pfizer and Johnson & Johnson will run with the biggest market share – respectively of USD 2.9bn, USD 2.1bn and USD 1.7bn by 2030.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs